Centauri Therapeutics secures £1m grant from PACE to advance antimicrobial immunotherapies.
Centauri Therapeutics has secured £1m from PACE to develop its Alphamer technology targeting drug-resistant bacterial strains.
A British biotechnology firm developing immunotherapies to combat drug-resistant bacterial infections using its proprietary Alphamer platform.
Centauri Therapeutics has secured a £1m grant from PACE to advance its antimicrobial immunotherapy programmes. The funding will support the continued development of the company's Alphamer technology, which targets drug-resistant bacterial strains. PACE selected the project during its initial funding round to help de-risk and accelerate early-stage drug discovery.
The investment will drive further research across multiple therapeutic indications. Centauri's approach leverages the body's natural antibody repertoire to redirect immunity towards pathogenic cells, offering a precision medicine alternative for vulnerable patients.
From the founder
"We are pleased that Centauri’s project was selected to be funded in the first round of projects under PACE, in recognition of the value of this novel immunotherapeutic technology"
Jennifer Schneider
Chief Executive Officer at Centauri Therapeutics
Investor perspective
"Centauri’s immunotherapy platform provides a unique approach to addressing the rising threat of difficult-to-treat infections – one of our most complex health challenges. By working together with the brightest and best, providing support to companies such as Centauri, we aim to give leading antimicrobial innovations the greatest chance of success, advancing early-stage drug and diagnostic projects with greater speed, support, and confidence."
Beverley Isherwood
Programme Director, PACE
Use of funds
- 01Fund research and development
- 02Continue product development
Investors
Categories
About the company
Centauri Therapeutics
Centauri Therapeutics develops novel immunotherapies to target multidrug-resistant Gram-negative bacteria.